ScreenerHero

MRK Merck KGaA

XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · merckgroup.com
141.95EUR+4.34%Mkt Cap: 64.30B $P/E: 24.96

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD
INDV
Indivior Pharmaceuticals, Inc.
$4.25BUSDP/E 12.9

Key Statistics

Company
Market Cap64.30B USD
Enterprise Value74.63B USD
Revenue (TTM)22.97B USD
Gross Profit13.42B USD
Net Income (TTM)2.83B USD
Revenue/Share48.63 EUR
Last Price141.95 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees62.1K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)24.96
P/E (Forward)15.36
PEG2.21
EV/EBITDA12.29
EV/Revenue3.25
P/S2.82
P/B1.97
EPS (TTM)5.45
EPS (Forward)8.91
52W Range
100.7086% of range148.80
52W High148.80 EUR
52W Low100.70 EUR
Profitability
Gross Margin58.51%
Oper. Margin13.86%
EBITDA Margin26.43%
Profit Margin12.36%
ROE9.12%
ROA5.06%
Growth
Revenue Growth3.40%
Earnings Growth-24.70%
Cash Flow & Leverage
Operating CF4.27B USD
CapEx (TTM)2.13B USD
FCF Margin12.46%
FCF Yield4.45%
Net Debt9.98B USD
Net Debt/EBITDA1.64
Balance Sheet
Debt/Equity0.42
Current Ratio1.70
Quick Ratio0.99
Book Value/Sh69.58 EUR
Cash/Share7.20 EUR
Dividends
Fwd Div Rate2.20 EUR
Trail. Div Rate2.20 EUR
Div. Yield1.61%
5Y Avg Yield1.28%
Payout Ratio40.37%
Ex-Div DateApr 27, 2026
Pay Date—
Splits
Last Split2:1
Split DateJun 30, 2014
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)154.21 EUR
Upside (mean)+8.6%
Target Range135.00 EUR – 179.00 EUR
135.00+8.6% to mean179.00
# Analysts14
Ownership
Shares Out.129.24M
Float128.87M
Insiders0.00%
Institutions57.80%
Technical
SMA 50137.77 (+3.0%)
SMA 200127.54 (+11.3%)
Beta0.81
S&P 52W Chg14.58%
Avg Vol (30d)276.14K
Avg Vol (10d)284.74K
Technical Indicators
RSI (14)51.5
MACD-0.0320
MACD Signal-0.6530
MACD Hist.+0.6210
BB Upper138.89 EUR
BB Middle133.69 EUR
BB Lower128.49 EUR
BB Width7.78%
ATR (14)2.806 EUR
Vol Ratio (20d)0.66x